ARID1A Mutations in Gastric Cancer: A Review with Focus on Clinicopathological Features, Molecular Background and Diagnostic Interpretation
Cancers · 30.05.2024 · 16 (11) · 2062
DOI: 10.3390/cancers16112062 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.05.2024. Verfasst von Giuseppe Angelico und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, Kore University of Enna, 94100 Enna, Italy. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union’s NextGenerationEU.
Abstract (Originalsprache)
AT-rich interaction domain 1 (ARID1A) is a pivotal gene with a significant role in gastrointestinal tumors which encodes a protein referred to as BAF250a or SMARCF1, an integral component of the SWI/SNF (SWItch/sucrose non-fermentable) chromatin remodeling complex. This complex is instrumental in regulating gene expression by modifying the structure of chromatin to affect the accessibility of DNA. Mutations in ARID1A have been identified in various gastrointestinal cancers, including colorectal, gastric, and pancreatic cancers. These mutations have the potential to disrupt normal SWI/SNF complex function, resulting in aberrant gene expression and potentially contributing to the initiation and progression of these malignancies. ARID1A mutations are relatively common in gastric cancer, particularly in specific adenocarcinoma subtypes. Moreover, such mutations are more frequently observed in specific molecular subtypes, such as microsatellite stable (MSS) cancers and those with a diffuse histological subtype. Understanding the presence and implications of ARID1A mutations in GC is of paramount importance for tailoring personalized treatment strategies and assessing prognosis, particularly given their potential in predicting patient response to novel treatment strategies including immunotherapy, poly(ADP) ribose polymerase (PARP) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) inhibitors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine and Surgery, Kore University of Enna, 94100 Enna, Italy.
- Department of Medical, Surgical Sciences and Advanced Technologies G.F. Ingrassia, Anatomic Pathology, University of Catania, 95123 Catania, Italy.
- Pathology Unit, Department of Experimental Oncology, Mediterranean Institute of Oncology, 95029 Catania, Italy.
- PhD Program in Precision Medicine, University of Palermo, 90144 Palermo, Italy.
- Department of Chemical, Biological and Environmental Chemistry, University of Messina, 98122 Messina, Italy.
- Medical Oncology Unit, Department of Experimental Oncology, Mediterranean Institute of Oncology, Viagrande, 95029 Catania, Italy.
ORCID-Profile: Giuseppe Angelico, Lorenzo Colarossi, Cristina Colarossi, Nicolas Orsi, Lorenzo Memeo
Förderung
- European Union’s NextGenerationEU
Zitieren
APA
Angelico, G., Attanasio, G., Colarossi, L., Colarossi, C., Montalbano, M., Aiello, E., Di Vendra, F., Mare, M., Orsi, N., & Memeo, L. (2024). ARID1A Mutations in Gastric Cancer: A Review with Focus on Clinicopathological Features, Molecular Background and Diagnostic Interpretation. Cancers, 16(11), 2062. https://doi.org/10.3390/cancers16112062
Vancouver
Angelico G, Attanasio G, Colarossi L, Colarossi C, Montalbano M, Aiello E, et al. ARID1A Mutations in Gastric Cancer: A Review with Focus on Clinicopathological Features, Molecular Background and Diagnostic Interpretation. Cancers. 2024;16(11):2062. doi:10.3390/cancers16112062
BibTeX
@article{Angelico2024,
author = {Angelico, Giuseppe and Attanasio, Giulio and Colarossi, Lorenzo and Colarossi, Cristina and Montalbano, Matteo and Aiello, Eleonora and Di Vendra, Federica and Mare, Marzia and Orsi, Nicolas and Memeo, Lorenzo},
title = {ARID1A Mutations in Gastric Cancer: A Review with Focus on Clinicopathological Features, Molecular Background and Diagnostic Interpretation},
journal = {Cancers},
year = {2024},
volume = {16},
number = {11},
pages = {2062},
doi = {10.3390/cancers16112062}
}
EUVIMED